Research

*April 2024* Highlights Additional frontline options for treating EGFR-mutated NSCLC are required. Lazertinib showed promising efficacy and safety in LASER201 and LASER301 trial. Long-term follow-up in LASER201 showed long PFS and OS with frontline lazertinib. Patients with and without baseline brain metastasis showed clinical benefit. Lazertinib was well tolerated, consistent…

*April 2024* IP is an effective treatment method for the EGFR-TKI-failed NSCLC-LM with a median OS of 12 months. Previous intrathecal methotrexate/cytarabine and whole-brain radiotherapy didn't have significant difference on IP treatment. IP is a safe treatment method for the EGFR-TKI-failed NSCLC-LM with tolerated adverse events. IP should be recommended…

*April 2024* Highlights Osimertinib is currently the common first-line therapy in EGFR-mutated non-small cell lung cancer patients. Understanding primary and acquired resistance mechanisms to osimertinib is crucial in choosing subsequent therapy strategy. Treatment after osimertinib must be tailored according to type of progression and detection of resistance mechanisms. Therapeutic strategies targeting…

*February 2024* The combination of osimertinib with platinum-pemetrexed led to improved central nervous system (CNS) efficacy vs osimertinib alone among patients with EGFR-mutated non–small cell lung cancer (NSCLC), according to findings from the phase 3 FLAURA2 study (NCT04035486).1 The phase 3 trial included 118 of 279 patients in the combination…

*February 2024* Co-occurring genetic alterations in solid tumors are a critical and influential prognostic factor that holds substantial importance in understanding the disease progression and guiding treatment strategies. Tumor cells acquire somatic mutations in both oncogenes and tumor suppressor genes (TSGs) leading to tumorigenesis.1  The event of multiple mutations emerging…

*March 2024* The FDA has approved amivantamab-vmjw (Rybrevant) plus carboplatin and pemetrexed for the frontline treatment of patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations, as detected by an FDA-approved test.1,2 The regulatory agency also granted full approval to amivantamab in adult patients…

*January 2024* This recorded webinar is an update on research supported by our joint grant! Hear from 2022 grant recipients Dr. Swarnali Acharyya, Dr. Luke Hoeppner, and Dr. Jonathan Ostrem.LCRF.  Watch here.

*January 2024* Dr. Shannon Westin and her guests, Dr. Judy Garber and Dr. Geoffrey Oxnard, discuss the paper "Germline EGFR Mutations and Familial Lung Cancer" recently published in the JCO. Listen to the podcast or read the transcript here.

*January 2024* In Part One of a two-part podcast on oligometastatic lung cancer, host Dr. Narjust Florez interviews Dr. Fatima Wilder about how local therapies, such as radiation, cryoablation, and surgery, impact the treatment of this complex form of lung cancer. In Part Two of this Lung Cancer Considered podcast…

*January 2024* Note: This article discusses the analysis of circulating tumor DNA (ctDNA) in the context of osimertinib treatment for non-small cell lung cancer (NSCLC), specifically focusing on resistance mechanisms. It highlights the complexity of resistance mechanisms associated with osimertinib treatment in NSCLC and the importance of understanding genetic changes for effective management.…